Fresenius SE & Co. KGaA has announced a strategic development agreement with TQ Therapeutics to enhance scalable and efficient manufacturing of cell and gene therapies. Through this partnership, Fresenius Kabi, an operating company of Fresenius, will receive an exclusive license to integrate TQ Therapeutics' proprietary cell selection technology into its Cue® Cell Processing System. The collaboration aims to streamline the isolation of high purity T cells, reducing the process to under two hours, and accelerate therapy development. This initiative supports Fresenius' strategy to focus on high-value healthcare platforms and expand access to advanced treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.